FilingReader Intelligence
Hubei Biocause Pharmaceutical advances voluntary delisting from Shenzhen
August 20, 2025 at 05:31 PM UTC•By FilingReader AI
Hubei Biocause Pharmaceutical is progressing with its voluntary delisting from the Shenzhen Stock Exchange, with shares suspended since August 14.
The company has been under delisting risk warning since July 8 due to failing to file its 2024 annual report and first-quarter 2025 report.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:000627•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Hubei Biocause Pharmaceutical publishes news
Free account required • Unsubscribe anytime